German-based startup attracts venture funding to address ‘Agitation/Aggression’ in Alzheimer’s disease
Exciva raises €9 million in Series A round
02-Nov-2021 -
Exciva GmbH, a clinical biotech startup developing a novel therapeutic compound for treating agitation/aggression in Alzheimer’s disease, announces the closing of a Series A financing of €9 million ($10M) led by Andera Partners. LBBW Venture Capital and Cure8 also participated in the round.
This ...
Alzheimer's disease
Series A financing